Publications

  • Besnard M, Sérazin C, Ossart J, Moreau A, Vimond N, Flippe L, Sein H, Smith GA, Pittaluga S, Ferré EM, Usal C, Anegon I, Ranki A, Lionakis MS, Peterson P, Guillonneau C.Anti-CD45RC antibody immunotherapy prevents and treats experimental Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy syndrome. 2022. J Clin Invest. doi: 10.1172/JCI156507.
  • Besnard M, Padonou F, Provin N, Giraud M, Guillonneau C. AIRE deficiency, from preclinical models to human APECED disease. 2021. Dis Model Mech. doi: 10.1242/dmm.046359.
  • Freuchet, A. A. Salama, S. Remy, C. Guillonneau* and I. Anegon*. IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases. 2021. J. Leuk. Biol. doi: 10.1002/JLB.3RU1120-773R.
  • Amini, L, J. Greig, M. Schmueck-Henneresse, H-D. Volk, S. Bézie, P. Reinke, C. Guillonneau*, D. L. Wagner*, I. Anegon*. Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications. 2021. Front. Immunol. doi: 10.3389/fimmu.2020.611638.
  • Boucault, M-D. Lopez Robles, A. Thiolat, S. Bézie, M. Schmueck-Henneresse, C. Braudeau, N. Vimond, A. Freuchet, E. Austrusseau, F. Charlotte, R. Redjoul, F. Beckerich, M. Leclerc, E. Piaggio, R. Josien, H-D. Volk, S. Maury, J. L Cohen, I. Anegon* and C. Guillonneau*. Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. 2020. Blood Adv. 4. 2501-2515. Read
  • Bézie, C., A. Freuchet, C. Sérazin, A. Salama, S. Usal, N. Vimond, I. Anegon* and C. Guillonneau*. IL-34 actions on FOXP3+ Tregs and CD14+ monocytes control human graft rejection. 2020. Front. Immunol. 11:1496. Read
  • Bézie S., B. Charreau, N. Vimond, J. Lasselin, N. Gérard, V. Nerrière-Daguin, F. Bellier-Waast, F. Duteille, I. Anegon* and C. Guillonneau*. Human CD8+ Tregs expressing a MHC-specific chimeric antigen receptor display enhanced suppression of human skin rejection and GVHD in NSG mice. 2019. Blood Adv. 3:3522. Read
  • Ouisse L-H., S. Remy, A. Lafoux, T. Larcher, L. Tesson, V. Chenouard, C. Guillonneau, L. Brusselle, N. Vimond, K. Rouger, Y. Péréon, A. Chenouard, C. Gras-Le Guen, C. Braudeau, R. Josien, C. Huchet, I. Anegon. Immunophenotype of a rat model of Duchenne’s disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment. 2019. Front. Immunol. 10:2131. Read
  • Bézie S., I. Anegon* and C. Guillonneau*. Advances on CD8+ Tregs and their potential in transplantation. 2018. Transplantation. 102 (9), 1467. Read
  • Bézie S., D. Meistermann, L. Boucault, S. Kilens, J. Zoppi, E. Autrusseau, A. Donnart, V. Nerrière-Daguin, F. Bellier-Waast, E. Charpentier, F. Duteille, L. David, I. Anegon* and C. Guillonneau*. Ex vivo expanded human non-cytotoxic CD8+CD45RClow/− Tregs efficiently delay skin graft rejection and GVHD in humanized mice. 2018. Frontiers in Immunology. 8:2014. Read
  • Guillonneau C*., S. Bézie, I. Anegon*. Immunoregulatory properties of the cytokine IL-34. 2017. Cellular and Molecular Life Science. 74: :2569. Read
  • Bézie S., L. Boucault, E. Autrusseau, S. Kilens, D. Meistermann, B. Martinet, V. Daguin, A. Donnart, E. Charpentier, L. David, I. Anegon* and C. Guillonneau*. Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells. 2017. J. Clin. Invest. Insight. 9;2(3):e90088. Read
  • Bézie, S., Picarda, E., Ossart, J., Tesson, L., Usal, C., Renaudin, K., Anegon, I.*, and Guillonneau, C*. Interleukin-34, a new Treg-specific cytokine mediator of transplant tolerance. 2015. J. Clin. Invest., 125(10):3952. Read
  • Picarda E., S. Bézie, V. Venturi, K. Echasserieau, E. Merieau, A. Delhumeau, K. Renaudin, S. Brouard, K. Bernardeau, I. Anegon and C. Guillonneau. Donor MHC-derived peptide recognized by TCR biased-CD8+ Tregs suppresses organ rejection. 2014. J. Clin. Invest, 124:2497-. Read
  • Li X-L., S. Ménoret, S. Bezie, L. Caron, D. Chabannes, M. Hill, F. Halary, M. Angin, M. Heslan, C. Usal, L. Liang, C. Guillonneau, B. Le Mauff, M-C. Cuturi, R. Josien, I. Anegon. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. 2010. J. Immunol. 185:823. Read
  • Guillonneau1 C., C. Séveno1, A-S. Dugast, X-L. Li, K. Renaudin, F. Haspot, C. Usal, J. Véziers, I. Anegon* and B. Vanhove*. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. 2007. J. Immunol. 179: 8164. Read
  • Guillonneau C., V. Aubry, K. Renaudin, C. Séveno, C. Usal, K. Tezuka, I. Anegon. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L costimulation blockade. 2007. Transplantation. 80:255. Read
  • Guillonneau C., M. Hill, F-X. Hubert, E. Chiffoleau, C. Hervé, X-L Li, M. Heslan, C. Usal, L. Tesson, S. Ménoret, A. Saoudi, B. Le Mauff, R. Josien, M. C. Cuturi and I. Anegon. CD40Ig treatment results in allograft acceptance mediated by CD8+CD45RClow T cells, IFNgamma and indoleamine 2,3 dioxygenase. 2007. J. Clin. Invest. 117 :1096. Read